My watch list
my.bionity.com  
Login  

3,557 Current news from the ressort products

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Potential New Treatment for Heart Attack

Prospective drug found by testing in human heart muscle grown from stem cells

11-Mar-2019

Domainex announced that a team of its scientists, working in close partnership with Professor Michael Schneider and his team at Imperial College, have found a potential new drug candidate for treating the heart damage caused during a heart attack by targeting the way the heart reacts to stress, ...

more

Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer

01-Mar-2019

Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and ...

more

CEPI awards US$ 34M contract to CureVac

28-Feb-2019

The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG have announced a partnership agreement worth up to US$ 34 million for the ongoing development of The RNA Printer™ prototype—a transportable, down-scaled, automated messenger RNA (mRNA) printing facility. This platform will ...

more

image description
University spinout receives £1.2 million to tackle antimicrobial resistance

04-Feb-2019

Amprologix Limited, a University of Plymouth spinout company, has won a £1.2 million contract from the Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs. Amprologix was ...

more

High-Tech Gründerfonds launches HTGF Academy for its startup portfolio

Tailored to the needs of startups

01-Feb-2019

At the High-Tech Partnering Conference, High-Tech Gründerfonds (HTGF) officially announced the launch of its HTGF Academy. The experience gained through 14 years of seed investment has shown that certain issues often arise for many startups. The offer of the HTGF Academy is exactly tailored to ...

more

image description
Investigational monoclonal antibody to treat Ebola is safe in adults

28-Jan-2019

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the National Institutes of ...

more

Atriva Therapeutics announces first closing of series A financing round

04-Jan-2019

Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds (HTGF). The Company founders and management joined the round, also. ...

more

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy

12-Dec-2018

Merck announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer (BTC). The FDA orphan drug designation follows the recent presentation ...

more

Camel-IDS EUR 37m Series A financing led by V-Bio Ventures

Life Science company to develop cancer targeted radiopharmaceuticals

16-Nov-2018

Camel-IDS, a VUB spin-off company developing cancer-targeted radiopharmaceuticals, today secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and ...

more

OMEICOS Therapeutics Closes €17m Series C Financing

Advancing lead candidate towards pivotal trials

05-Nov-2018

OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new ...

more

Page 2 From 356
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE